title: Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
abstract: Capecitabine monotherapy was administered for 25 patients with advanced or recurrent breast cancer, and the clinical therapeutic efficacy and its relationship to expression of 5-fluorouracil-related enzymes (i. e., thymidine phosphorylase (TP), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD)) were investigated. The expressions of TP, TS and DPD were determined by immunohistochemical staining techniques and rated using a scoring system of 1~4. The expression score for TP/DPD showed a statistically significant correlation with the clinical response, whereas the expression score for TP/TS also showed a correlation but it was not statistically significant. The number of patients was small, but the results revealed the potential of application of the TP/DPD expression score as a factor for predicting the efficacy of the drug in individual patients.
authors.affiliation: Department of Oncological and Regenerative Surgery, Institute of Health Biosciences Department of Surgery, The University of Tokushima Graduate School, Tokushima, Japan.
authors.forename: Junko
authors.initials: J
authors.lastname: Honda
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Sasa
authors.forename: Takuya
authors.initials: T
authors.lastname: Moriya
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Bando
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Hirose
authors.forename: Masako
authors.initials: M
authors.lastname: Takahashi
authors.forename: Taeko
authors.initials: T
authors.lastname: Nagao
authors.forename: Akira
authors.initials: A
authors.lastname: Tangoku
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000032:analysis / Q000378:metabolism*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005544:Forecasting; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D012189:Retrospective Studies; D013810:Therapeutic Equivalency; D013939:Thymidine Phosphorylase / Q000032:analysis / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D042943:Dihydrouracil Dehydrogenase (NADP); D013939:Thymidine Phosphorylase; D005472:Fluorouracil